22.07

1.21% -0.27

After Hours: 22.20 0.13 +0.59%

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $22.07, with a volume of 527.85K. It is down -1.21% in the last 24 hours and up +1.38% over the past month. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Previous Close:

$22.34

Open:

$22.5

24h Volume:

527.85K

Relative Volume:

0.58

Market Cap:

$2.63B

Revenue:

$434.48M

Net Income/Loss:

$68.15M

P/E Ratio:

21.85

EPS:

1.01

Net Cash Flow:

$114.96M

1W Performance:

+2.75%

1M Performance:

+1.38%

6M Performance:

+38.98%

1Y Performance:

+57.08%

1-Day Range:

$21.90

$22.62

1-Week Range:

$21.13

$23.02

52-Week Range:

$13.00

$24.27

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

167

Twitter

@CatalystForRare

Next Earnings Date

2024-11-06

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX Catalyst Pharmaceuticals Inc	22.07	2.63B	434.48M	68.15M	114.96M	0.54
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Initiated	Stephens	Overweight
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

Nov 29, 2024

Catalyst Pharmaceuticals director Harper sells $385,000 in stock - Investing.com

Nov 29, 2024

Catalyst Pharmaceuticals chief compliance officer sells $286,703 in stock - Investing.com

Nov 29, 2024

Capstone Investment Advisors LLC Takes $708,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 29, 2024

FORA Capital LLC Takes $516,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 29, 2024

Nov 27, 2024

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Nov 27, 2024

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance

Nov 27, 2024

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis - MarketBeat

Nov 27, 2024

Nov 25, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Nov 25, 2024

Catalyst Pharmaceuticals Recognized as One of North - GlobeNewswire

Nov 25, 2024

Segall Bryant & Hamill LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 25, 2024

Nov 23, 2024

Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock - Investing.com India

Nov 23, 2024

Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock By Investing.com - Investing.com South Africa

Nov 23, 2024

Nov 22, 2024

Catalyst Pharmaceuticals chairman sells $3.6 million in stock By Investing.com - Investing.com South Africa

Nov 22, 2024

Catalyst Pharmaceuticals Insider Trades Send A Signal - Benzinga

Nov 22, 2024

Pacer Advisors Inc. Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 22, 2024

Quest Partners LLC Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Nov 22, 2024

Nov 21, 2024

Catalyst Pharmaceuticals chairman sells $3.6 million in stock - Investing.com

Nov 21, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Nov 21, 2024

Nov 20, 2024

Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Nov 20, 2024